Largest Biomedical IPO of 2020: RemeGen

Largest Biomedical IPO of 2020: RemeGen

New drug approval: Telitacicept On March 12, the State Food and Drug Administration in China issued an announcement, authorizing conditional approval for RemeGen’s therapeutic biological product for injection, Telitacicept. The drug is an innovative drug TACl-Fc...

Analysis of Fourth-Generation EGFR Inhibitors

EGFR-TKI Lung cancer contributes to the highest number of new and fatal cases of malignant tumors in the world with regards to cancer cases. About 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Most patients with NSCLC often have mutations that lead...
How will new dual-acting drugs affect the ADHD market?

How will new dual-acting drugs affect the ADHD market?

Author: HE Sheng Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children. Guidelines within the American Psychiatric Association’s Diagnostic and Statistical Manual, Fifth edition (DSM-5) are used to diagnose ADHD....